



HAL
open science

Mutation screening of the EYA1, SIX1 and SIX5 genes in a large cohort of patients harboring branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations

Pauline Krug, Vincent Moriniere, Sandrine Marlin, Gabriel Heinz, Valérie Koubi, Dominique Bonneau, Estelle Colin, Remi Salomon, Corinne Antignac, Laurence Heidet

► To cite this version:

Pauline Krug, Vincent Moriniere, Sandrine Marlin, Gabriel Heinz, Valérie Koubi, et al.. Mutation screening of the EYA1, SIX1 and SIX5 genes in a large cohort of patients harboring branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations. *Human Mutation*, 2011, 32 (2), pp.183. 10.1002/humu.21402 . hal-00612007

HAL Id: hal-00612007

<https://hal.science/hal-00612007>

Submitted on 28 Jul 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Mutation screening of the EYA1, SIX1 and SIX5 genes in a large cohort of patients harboring branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0402.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	12-Oct-2010
Complete List of Authors:	<p>Krug, Pauline; AP-HP Service de Néphrologie Pédiatrique Hôpital Necker 149 rue de Sèvres Moriniere, Vincent; AP-HP, Département de Génétique, Hôpital Necker, 149 rue de Sèvres Marlin, Sandrine; AP-HP, Service de Génétique, Centre de Référence des Surdités Congénitales et Héritaires, Hôpital Trousseau Heinz, Gabriel; Diagenos Koubi, Valérie; AP-HP, Département de Génétique, Hôpital Necker, 149 rue de Sèvres Bonneau, Dominique; Service de Génétique, Hôpital d'Angers Colin, Estelle; Service de Génétique, Hôpital d'Angers Salomon, Remi; APHP Service de Néphrologie Pédiatrique Hôpital Necker 149 rue de Sèvres; AP-HP Centre de référence des maladies rénales héréditaires de l'enfant et de l'adulte Antignac, Corinne; Université Paris Descartes Heidet, Laurence; AP-HP, Centre de Référence des Maladies Rénales Héritaires de l'Enfant et de l'Adulte, Service de Néphrologie Pédiatrique</p>
Key Words:	BOR syndrome , EYA1, SIX1 , SIX5, developmental defects

SCHOLARONE™
Manuscripts

Mutation screening *of the EYAI, SIX1 and SIX5 genes in a large cohort of patients*

harboring branchio-oto-renal syndrome *calls into question the pathogenic role of SIX5*
mutations.

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: suggests that

Deleted: may not be disease-causing mutations

Pauline Krug¹, Vincent Morinière^{2,3}, Sandrine Marlin⁴, Valérie Koubi³, Heinz D Gabriel⁵, Estelle Colin⁶, Dominique Bonneau⁶, Rémi Salomon^{1,2,7}, Corinne Antignac^{3,7,8} and Laurence Heidet^{1,2}.

1 : AP-HP, Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris France

2 : AP-HP, Centre de Référence des Maladies Rénales Héritaires de l'Enfant et de l'Adulte (MARHEA)

3 : AP-HP, Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France

4 : AP-HP, Service de Génétique, Centre de Référence des Surdités Congénitales et Héritaires, Hôpital Trousseau, Paris, France

5 : Diagenos, Osnabrueck, Germany

6: Service de Génétique, Hôpital d'Angers, France

7 : Université Paris Descartes, Paris, France

8 : Inserm U983, Hôpital Necker, Paris France

Corresponding Author: Laurence Heidet, M.D., Ph.D
 Centre de Référence des Maladies Rénales Héritaires de l'Enfant et de l'Adulte (MARHEA)
 Service de Néphrologie Pédiatrique
 Hôpital Necker-Enfants Malades
 149 rue de Sèvres
 75015 Paris, France
 Tel : +33-1-44-49-43-82, Fax : +33-1-71-19-64-45
 E-mail: laurence.heidet@nck.aphp.fr

Key Words: BOR syndrome, *EYAI, SIX1, SIX5*, developmental defect

Deleted: ¶

Deleted: ¶

Formatted: English (U.K.)

Field Code Changed

Formatted: English (U.K.)

Formatted: English (U.K.)

Formatted: Indent: First line: 0 pt

Formatted: Font: Italic, English (U.K.)

Formatted: English (U.K.)

Formatted: Font: Italic, English (U.K.)

Formatted: English (U.K.)

Formatted: Font: Italic, English (U.K.)

Formatted: English (U.K.)

ABSTRACT

Branchio-oto-renal (BOR) syndrome is an autosomal dominant disorder characterized by branchial, ear and renal anomalies. Over 80 mutations in *EYA1* have been reported in BOR. Mutations in *SIX1*, a DNA binding protein that associates with EYA1, have been reported less frequently. One group has recently described 4 missense mutations in *SIX5* in 5 unrelated patients with BOR.

Here, we report a screening of these three genes in a cohort of 140 patients from 124 families with BOR. We identified 36 *EYA1* mutations in 42 unrelated patients, 2 mutations and one change of unknown significance in *SIX1* in 3 unrelated patients, but no mutation in *SIX5*. We did not find correlation between genotype and phenotype, and observed a high phenotypic variability between and within BOR families. We show the difficulty in establishing a molecular diagnosis strategy in BOR syndrome: the screening focusing on patients with typical BOR would detect a mutation rate of 76%, but would also miss mutations in 9% of patients with atypical BOR. We detected a deletion removing three *EYA1* exons in a patient who was previously reported to carry the *SIX5* Thr552Met mutation. This led us to reconsider the role of *SIX5* in the development of BOR.

Formatted: Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers

Deleted: the screening of only patients with typical BOR would lead to a 76% rate of mutation detection but would also miss mutations in 9% of atypical BOR

Deleted: .

INTRODUCTION

Branchio-oto-renal (BOR) syndrome is an autosomal-dominant developmental disorder which is characterized by hearing loss, branchial arch defects and various renal anomalies. The prevalence of BOR syndrome is estimated to be 1 case per 40 000 (Chen et al., 1995; Fraser et al., 1978; Fraser et al., 1980, Melnick et al., 1975, Melnick et al., 1978). The syndrome is clinically heterogeneous and has a high penetrance with variable expressivity (Fraser et al., 1978, Fraser et al., 1980, Chen et al., 2004). BOR syndrome is also genetically heterogeneous.

Over 80 mutations in *EYA1* ([MIM ID 601653](#)), the human homolog of the *Drosophila eyes absent* gene, encoding a transcriptional regulator, have been identified. These include large and small heterozygous deletions, frameshift, stop, splice-site and missense heterozygous mutations (Abdelhak et al., 1997b, Ni et al., 1994, Vincent et al., 1997). The rate of detection of *EYA1* mutations varies from 7% to 40% of patients tested according to the clinical criteria required for molecular testing (Abdelhak et al., 1997a, Abdelhak et al., 1997b, Chang et al., 2004, Orten et al., 2008). Mutations in *SIX1* ([MIM ID 601205](#)) (mainly missense mutations and small deletions), the human homolog of *sine oculis* encoding a DNA binding protein that associates with EYA1, have also been associated with BOR syndrome (Kochhar et al., 2008, Ruf et al., 2003, Ruf et al., 2004, Sanggaard et al., 2007), though much less frequently than *EYA1* mutations. More recently, missense mutations in another *SIX* family member, *SIX5* ([MIM ID 600963](#)), have been reported by one group in patients with BOR syndrome (Hoskins et al., 2007). *SIX5* homologous is known to interact with *eya-1* in *C. elegans*. *In vitro* functional analyses of the BOR-associated *SIX5* variants showed that some of these variants modified EYA1-SIX5 binding and the ability of the EYA1-SIX5 complex to transactivate a

Deleted: KEYWORDS: BOR syndrome, developmental defects, *EYA1*, *SIX1* and *SIX5* genes]

Deleted: nonsense

1
2 reporter gene (Hoskins et al., 2007). However, the association of *SIX5* mutations with BOR
3
4 syndrome has not been confirmed by other groups.

5
6 In the present study, we screen for *EYAI*, *SIX1* and *SIX5* mutations a large cohort of patients
7
8 with BOR syndrome. We describe the clinical features associated with the mutations and the
9
10 rate of mutations identified, according to the clinical phenotypes. We also show that one
11
12 family previously reported as carrying a *SIX5* missense mutation harbors a heterozygous
13
14 deletion of three *EYAI* exons, which therefore questions the role of the reported *SIX5* change.
15
16
17

18 PATIENTS AND METHODS

19 Patients

20
21 A total of 140 patients from 124 families with a diagnosis of BOR syndrome were included in
22
23 the study. Subjects were classified according to the criteria defined by Chang (Chang et al.,
24
25 2004) on the basis of clinical history, audiometry and renal ultrasonography. Patients were
26
27 considered as typical BOR when they had at least three major criteria (branchial anomalies,
28
29 deafness, preauricular pits or renal anomalies), or two major and two minor criteria (internal,
30
31 middle and/or external ear anomalies, preauricular tags, facial asymmetry or palatine
32
33 anomalies) or one major criterion and an affected first-degree relative meeting the above
34
35 criteria for typical BOR. Other were considered as atypical BOR and were tested only when
36
37 they demonstrated at least two features of the syndrome.
38

39 Patient 1062 was previously reported as carrying a heterozygous *SIX5* c.1655C>T
40
41 (p.[Thr552Met](#)) mutation (patient A500 in Hoskins et al.). His DNA had been tested for *EYAI*
42
43 mutations by direct sequencing, but not for abnormal copy number (Hoskins et al., 2007).
44

45 This patient was having assisted reproduction, and thus was making inquiries regarding the
46
47 possibility of preimplantation genetic testing.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Patients' samples, medical records, genealogy and written informed consent from patient
3
4 and/or parents were sent from Paediatric, Paediatric Nephrology, Nephrology, or Genetics
5
6 departments between August 2004 and December 2009.
7
8
9

10 **Mutation analysis**

11 Genomic DNA was isolated from peripheral blood using standard methods. The 16 exons of
12
13 *EYAI* were screened for mutations by direct sequencing. When no mutation was found,
14
15 quantitative multiplex PCR amplification of short fluorescence fragments (Charbonnier et al.,
16
17 2000) was performed for *EYAI* exons 1, 5, 10, 15 and 16. When a deletion was found to
18
19 remove some but not all of the exons tested, the DNA sample was analysed by multiplex
20
21 ligation dependent probes amplification (Salsa MLPA kit P153 EYA1, MRC-Holland,
22
23 Amsterdam, Netherlands). When neither mutation nor deletion was found in *EYAI*, the 2
24
25 exons of *SIX1* and the 3 exons of *SIX5* were screened by direct sequencing. For previously
26
27 unreported missense mutations, 92 control individuals were tested by direct sequencing. The
28
29 cDNAs NM_172060.2 for *EYAI*, NM_005982.3 for *SIX1* and NM_175875.4 for *SIX5* were
30
31 used for numbering, with nt +1 corresponding to the A of the ATG translation initiation
32
33 codon. One DNA sample (patient 608), was shown to have large 8q13.3 deletion by FISH
34
35 analysis and was used as a positive control for deletion screening. Missense mutations were
36
37 evaluated using the software PolyPhen (<http://genetics.bwh.harvard.edu/pph/>) and ConSurf
38
39 (<http://consurftest.tau.ac.il/>).
40
41
42

Formatted: Font: (Default) Times
New Roman

Formatted: Font: (Default) Times
New Roman, Not Bold

Deleted: .

43 **Statistical tests**

44
45 Testing for difference in proportions was performed using either the X^2 or Fisher's exact test.
46
47 All tests were two sided. *P*-values <0.05 were considered significant.
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Mutations

The mutations identified and the associated phenotypes are shown in table 1. In the entire cohort (140 patients from 124 families) we identified 36 *EYAI* mutations in 42 families (55 patients), two *SIX1* mutations and one *SIX1* variant of unknown significance in 3 families (4 patients), but no *SIX5* mutation. We identified two *SIX5* variants which were not considered to be responsible for the phenotype: one was found in controls, and the other, previously reported as a disease causing mutation in two families (Hoskins et al., 2007), was associated with a partial *EYAI* deletion in one of these two families included in our cohort. Therefore, mutations were identified in 36% (45/124) of the tested families.

EYAI gene analysis

Thirty-six *EYAI* heterozygous mutations, spread over the entire length of the gene (figure 1), were identified in 42 probands (table 1). Thirty-three were small mutations (8 missense including a mutation of the stop codon, 14 frameshift, 6 stop, and 5 splice-site mutations), and 24 of these were novel. All missense mutations but one [c.319G>A (p.Gly107Ser)] were considered as possibly or probably damaging by the PolyPhen software (<http://genetics.bwh.harvard.edu/pph/>). That mutation c.319G>A, which appeared *de novo* in the patient, was scored as benign by Polyphen but was in the last base of exon 4 and thus was expected to modify the splicing of intron 4 (GeneSplicer score changes from 6.97 to 2.49). Amino acid conservation scores according to ConSurf (varying from 1 to 9) for previously unpublished missense mutations are shown in table 1. Two previously reported mutations, c.982C>T and c.1220G>A, were respectively found in three and two unrelated patients. Three different deletions were identified in 5 unrelated patients by quantitative multiplex PCR amplification of short fluorescence fragments. In 3 of these probands (patients 608, 821, 991) all tested exons were missing and the deletion was considered to remove the entire gene. In

Deleted: 2

Deleted: nonsense

Formatted: Font: Italic

Deleted: ,

Deleted: was

1
2 | the other two cases, the deletion was partial and its precise extent was determined by MLPA
3
4 | analysis: one removed exons 8 to 16 (patient 1216) and one removed exons 3, 4 and 5
5
6 | (patients 1062, 1063 and 1064). Patient 1062 was one of the 2 probands previously reported to
7
8 | carry the *SIX5* p.Thr552Met mutation (patient A500 in Hoskins, et al., 2007). Parent status
9
10 | was tested for 26 probands with an identified *EYAI* mutation : 8 mutations out of 26 were *de*
11
12 | *novo* and 18 were inherited.

13 14 15 16 ***SIX1* gene analysis**

17
18 Three different, potentially pathogenic variations in *SIX1* were identified in 3 families (table
19
20 | 1). The *SIX1* mutation (p.Tyr129Cys) has already been described (Ruf et al., 2004), and
21
22 | affects a conserved tyrosine in the homeodomain. It is predicted to be probably damaging by
23
24 | Polyphen (score 2.945), and inhibits the transcription activation *in vitro* (Patrick et al., 2009).
25
26 | This mutation was also present in the affected father of the proband. The mutation
27
28 | c.560+3A>T, probably leading to aberrant splicing (GeneSplicer score changes from 9.74 to
29
30 | 2.89), has never been previously described. Finally, the c.746C>T change in exon 2 affects a
31
32 | strongly conserved amino acid (p.Pro249Leu) and was considered as possibly damaging by
33
34 | PolyPhen (score 1.806). Although this change was not present in 92 healthy control
35
36 | chromosomes it is located in a region of unknown function and replaces a non polar side
37
38 | chain amino acid with another amino acid of the same family. The segregation of these two
39
40 | last changes could not be tested because DNA samples from family members were not
41
42 | available.

43 44 45 46 ***SIX5* gene analysis**

47
48 We did not identify any novel *SIX5* mutations in our entire cohort. We confirmed the finding
49 | of the *SIX5* p.Thr552Met heterozygous variant in patient 1062, and also found the same *SIX5*
50
51
52
53
54
55
56
57
58
59
60

1
2 variant in his twin brother (patient 1063) and in his father (patient 1064), who were both
3 affected. This variant was predicted as possibly damaging by the Polyphen program (score
4 1.711). However, we identified an *EYA1* partial deletion in the three affected members of this
5 family (see above). We found another *SIX5* variant, [c.156_161dup \(p.Gly55Ala56dup\)](#), in a
6 patient from Guadeloupe. That variant, which introduces two amino acids in the N-terminus
7 of the protein, was also found in 3/86 controls from the West Indies and thus was considered
8 as non pathogenic.
9
10
11
12
13
14
15
16
17

Deleted: (figure 2)

Deleted: c.161_162insCGGGGC
(p.54_55 ins GA)

18 Phenotypes (tables 1 and 2)

19 According to previously described criteria (Chang et al., 2004), our population included 67
20 patients with typical BOR and 55 patients with atypical BOR. In 18 cases the information we
21 had was insufficient to classify patients as typical or atypical. Sixty eight probands had a
22 family history of BOR (38 typical cases of BOR and 30 cases of renal anomaly, branchial
23 arches defects and/or deafness, which did not fulfill the typical BOR diagnosis criteria). The
24 phenotypic features of patients with an identified mutation are detailed in table 1.
25
26
27
28
29
30

31 The frequency of each symptom in our entire population as well as in patients with mutation
32 and in patients without mutation is summarized in table 2. The various renal phenotypes
33 observed in patients with an identified mutation are described figure 2. The renal function of
34 these patients varied greatly, from a normal glomerular filtration rate to end-stage renal
35 failure. In four cases prenatal renal failure diagnosed by oligoamnios during the second
36 trimester of pregnancy was observed in fetuses displaying kidney hypoplasia (patients 175,
37 700, 991 and 1126), and this led to termination of pregnancy in three of these cases. Five
38 patients received a renal transplant: two reached end stage renal failure during childhood (at
39 14 and 16 years), one at 26 years, and two others at unknown age (but one received a
40 transplant at 22). In some families (see cases 700 and 1126 as examples), although a fetus or a
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: 3

Deleted: o

1
2 child had severe renal disease, the affected parent had normal renal function and normal
3 kidneys on ultrasound examination. After renal disease, the most frequent symptom was
4 deafness (conductive and/or sensorineural), followed by pits, branchial defect and then by ear
5 tags.
6
7
8
9

Deleted: on

10 Some patients presented with rare phenotypic features. In patients with an identified mutation,
11 two (patients 311 and 1291) presented with cataract (unilateral in one case and bilateral in the
12 other). Five patients had facial nerve impairment: unilateral facial paralysis, crocodile tears
13 syndrome and facial asymmetry. Palate anomalies were observed in 5 patients: short palate
14 responsible for hypernasal speech, arched palate, palatine cleft, bifid uvula and posterior
15 agenesis of uvula. We observe two heart defects: a persistent ductus arteriosus in patient 708
16 and a conotruncal cardiopathy (pulmonary atresia with interventricular communication) in
17 patient 700. Finally, patient 229 suffered from hypothyroidism of unknown etiology.
18
19
20
21
22
23
24
25

Deleted: d

26 In patients without any identified mutation, rare clinical features were also observed : palate
27 or laryngeal anomalies (n=4), facial asymmetry (n=2), bifid uterus (n=2), interventricular
28 communication (n=2), clinodactyly (n=1), aortic arch hypoplasia (n=1), cutaneous
29 pigmentation anomalies (n=2), Malherbe's calcifying epithelioma (n=1), dorsal medullar
30 atrophie responsible for pyramidal syndrome (n=1), pulmonary hypertension of unknown
31 etiology (n=1), cerebral ventricular dilation (n=1), thyroglossal duct cyst (n=1), jejuno-ileal
32 atresia (n=1), and bone anomalies (radial aplasia, mandibular hypoplasia, dental agenesis,
33 postaxial polydactyly) in four patients.
34
35
36
37
38
39
40

41 **Genotype-phenotype correlation**

42 Because the type and severity of the symptoms were very variable, we searched whether there
43 was a correlation between the phenotype and either the mutated gene (*EYA1* or *SIX1*) or the
44 type of mutation (missense mutation, truncating mutation because of stop, frameshift, or
45 splice-site mutation), or deletion. Of the 67 patients with typical BOR syndrome, 50 (75%),
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: nonsense

1
2 had a mutation in *EYAI*, and one had a change in *SIX1* of unknown significance. Of the 55
3
4 patients with atypical BOR syndrome, 5 (9%) had a mutation (in *EYAI* in 4 cases and in *SIX1*
5
6 in 1 case). The proportion of patients affected with typical or atypical BOR syndrome was not
7
8 significantly different ($p=0.38$) between patients carrying a missense mutation (9/11 typical),
9
10 a truncating mutation (34/37 typical) or a deletion (8/8 typical). The same mutation
11
12 (p.Arg328X) was identified in a patient with atypical BOR and in 2 patients with typical
13
14 BOR. We did not observed any particular phenotypic features associated with *SIX1* mutations.
15
16 Rare features were observed both in patients carrying *EYAI* or *SIX1* mutations (assuming that
17
18 the *SIX1* p.Pro249Leu is responsible for the phenotype). Among the 55 patients with *EYAI*
19
20 mutations, the proportion of deletion (n=9), missense (n=10), and truncating (n=36) mutations
21
22 was not significantly different between patients with (n=40) or without (n=15) deafness
23
24 ($p=0.46$), with (n=30) or without (n=25) kidney involvement ($p=0.35$), with (n=32) or without
25
26 (n=23) pits ($p=1$), or with (n=34) or without (n=11) branchial defect ($p=0.66$) (Table 3).
27
28 Regarding the renal disease, cases with prenatal renal failure associated with oligoamnios
29
30 (n=4) or with severe renal failure leading to renal transplant (n=5) were associated with *SIX1*
31
32 mutations in one case, and with *EYAI* mutations in 7 cases. These proportions were not
33
34 significantly different from that observed in all patients. However, in the 7 cases with *EYAI*
35
36 mutations, none of these mutations were a missense mutations (3 were frameshift, 1 splice-
37
38 site, 1 stop and 2 were entire gene deletions).

Deleted: nonsense

DISCUSSION

41
42
43 To our knowledge, this study is the first one to analyze all of the genes currently known to be
44
45 implicated in BOR syndrome in a large cohort of patients. Overall, we detected a mutation in
46
47 45/124 (36%) probands. Forty two probands were carrying an *EYAI* mutation thought to be
48
49 pathogenic. However, the impact of the c.867+5G>A change on mRNA splicing has not yet
50
51
52
53
54
55
56
57
58
59
60

1
2 been demonstrated. Three probands were carrying mutations in *SIX1*. Of these, one (patient
3
4 714) was carrying the c.806C>T, p.Pro249Leu change, which has never been described
5
6 before, and is predicted to be possibly damaging by Polyphen. This mutation was not found in
7
8 92 control chromosomes, but does not affect a protein domain with a known function. All
9
10 other *SIX1* mutations reported so far affect either the SIX or the homeodomain encoding
11
12 nucleotides (Kochhar et al., 2008, Ruf et al., 2004). We were unable to test other family
13
14 members of patients 714 and 715, so it is difficult to conclude whether this change is or not a
15
16 disease-causing mutation.

17
18 In our entire cohort, we did not identify any pathogenic mutation in the *SIX5* gene. In one
19
20 patient previously reported to carry a *SIX5* missense variant (case 1062), we found a partial
21
22 (exons 3-5) *EYA1* deletion. The three affected patients in this family were carrying both the
23
24 *EYA1* deletion and the *SIX5* variant. We believe that the *EYA1* deletion is responsible for the
25
26 phenotype in this family, though we cannot rule out the hypothesis that the *SIX5* variant may
27
28 modify the *EYA1*-associated phenotype. However, whereas the three patients had deafness,
29
30 the renal disease was more severe in the two siblings (undergoing renal transplantation at 22
31
32 and 23 years of age) than in their father (who had not reached end-stage renal failure at 58
33
34 years). This was despite the fact that all three carried the *SIX5* variant. The finding of an *EYA1*
35
36 mutation in that family made us reconsider the role of *SIX5* in the development of BOR
37
38 syndrome. Among the 5 index cases reported by Hoskins et al. as carrying a *SIX5* mutation
39
40 (Hoskins et al., 2007), all carried a missense variant, including two cases with the c.1655C>T
41
42 p.Thr552Met variant (patient 1062 and another patient). The segregation of the variants with
43
44 the phenotype had not been studied. These variants modestly (20 to 48%) although
45
46 significantly decreased the ability of *SIX5/EYA1* to activate gene transcription *in vitro*
47
48 (Hoskins et al., 2007). No other *SIX5* mutation (whether missense or other type of
49
50 mutation/rearrangement) has been reported since this initial report. In addition, whereas mice
51
52
53
54
55
56
57
58
59
60

Deleted:

Deleted: Only two of the

Deleted: modified

1
2 with *Six1* or *Eya1* gene inactivation develop ear and kidney abnormalities, the phenotype in
3
4 *Six5*^{-/-} mice is limited to abnormalities in the eye (cataract), and does not affect the ear or the
5
6 kidney. Taken together, these findings strongly suggest that *SIX5* mutations are not directly
7
8 responsible for BOR syndrome.

9
10 Among the patients that were classified with either typical or atypical BOR (122 patients), we
11
12 identified a mutation in 75% of cases with typical BOR syndrome and in 9% of cases with
13
14 atypical BOR syndrome. These results are different from those reported recently in a smaller
15
16 cohort in which no mutations were detected in any subject with atypical BOR (Rickard et al.,
17
18 2008). This highlights the difficulty in reconciling the need for performing molecular testing
19
20 in a consequential and cost effective manner, and the fact that a screening limited to typical
21
22 BOR syndrome will miss few mutations and prevent accurate genetic counselling in these few
23
24 families. The rate of mutation that we report here is not different from that recently reported
25
26 in another large cohort (Orten et al., 2008). However, the rate of *EYAI* deletion in the present
27
28 study is lower than that (18%) reported by Chang et al. (Chang et al., 2004). Although we
29
30 used the same semiquantitative fluorescence multiplex PCR approach for tracking *EYAI*
31
32 deletions, we only tested exons 1, 5, 10, 15, and 16 in a first attempt. We may have thus
33
34 missed small or complex deletions involving other exons.

35
36 In our series as in others (Chang et al., 2004, Ruf et al., 2004, Saanggard et al., 2007, Okada
37
38 et al., Orten et al., 2008), the type and severity of the phenotype does not seem to correlate
39
40 with the type of mutation and is very variable, even within a given family. Only the severity
41
42 of renal failure may correlate to some extent with the type of *EYAI* mutation, as none of the 7
43
44 patients with the most severe renal insufficiency were carrying a missense mutation. However
45
46 the small number of patients does not allow any conclusion to be made, and it would be
47
48 interesting to analyze the severity of the renal failure in a larger number of cases carrying an
49
50 *EYAI* mutation. The high frequency of renal anomalies in our series may be due to the fact

1
2 that our laboratory is focused on renal diseases. The important phenotypic variability
3
4 observed in our cohort as in others may be due to genetic and/or environmental factors (in
5
6 particular maternal factors during embryonic and fetal development) that modify the
7
8 phenotype. This makes genetic counselling particularly difficult for these families.

9
10 We report some interesting clinical features associated with *EYAI* mutations. Although
11
12 already reported by others (Chen et al., 1995, Shimasaki et al., 2004) the association with
13
14 hypothyroidism or with persistent ductus arteriosus may be fortuitous, as may be the
15
16 association with a conotruncal cardiopathy. Two patients suffered from cataract, which could
17
18 be associated with a defect of early expression of *EYAI* in the anterior ocular segment, and
19
20 has already been described (Azuma et al., 2000). A facial nerve impairment was present in six
21
22 patients, which may be explained by anomalies of inner ear, affecting the nerve trajectory.

23
24 In conclusion, our results confirm that *EYAI* is by far the most frequently mutated gene in
25
26 BOR syndrome today and seriously question the role of *SIX5* variants in the pathophysiology
27
28 of BOR syndrome. They confirm the lack of genotype-phenotype correlation and illustrate the
29
30 difficulty in establishing an algorithm for molecular diagnosis in BOR syndrome. The
31
32 screening of patients with typical BOR only would greatly increase the rate of identified
33
34 mutations but would also lead to missed mutations in a few families. Our data suggest that
35
36 testing patients with atypical BOR still results in the identification of a few mutations, but
37
38 screening of the *SIX5* gene can be given up.

39 40 41 **Acknowledgments**

42
43 We thank the patients and their family for their participation. We are grateful to the following
44
45 physicians for contribution of material and clinical data from patients : Pr Melki (AP-HP
46
47 Hôpital de Bicetre, France), Dr Toutain (Hôpital de Tours, France), Pr Bensman (AP-HP,
48
49 Hôpital Trousseau, Paris, France), Dr Cartault (Hôpital de St Denis, France), Dr Blesson

Formatted: English (U.S.)

(Hôpital de Tours, France), Pr Cochat (Hôpital de Lyon, France), Dr Demeer (Hôpital d'Amiens, France), Pr Dollfus (Hôpital de Strasbourg, France), Dr Drouin (Hôpital de Rouen, France), Dr Faivre (Hôpital de Dijon, France), Dr Duban-Bedu (Hôpital de Lille, France), Pr Grunfeld (AP-HP, Hôpital Necker, Paris, France), Pr Lacombe (Hôpital de Bordeaux, France), Pr Manach (AP-HP, Hôpital Necker, Paris, France), Pr Cormier-Daire (AP-HP, Hôpital Necker, Paris, France), Dr Mathieu (Hôpital d'Amiens, France), Dr Francannet (Hôpital de Clermont-Ferrand, France), Pr Manouvrier (Hôpital de Lille, France), Dr Baumann (AP-HP, Hôpital Robert Debré, Paris, France), Dr Isidor (Hôpital de Nantes, France), Pr Deschênes (AP-HP, Hôpital Robert Debré, Paris, France), Dr Dupin-Deguine (Hôpital de Toulouse, France).

REFERENCES

- Abdelhak S, Kalatzis V, Heilig R, Compain S, Samson D, Vincent C, Levi-Acobas F, Cruaud C, Le Merrer M, Mathieu M, König R, Vigneron J, Weissenbach J, Petit C, Weil D. 1997a. Clustering of mutations responsible for branchio-oto-renal (BOR) syndrome in the eyes absent homologous region (*eyaHR*) of *EYA1*. *Hum Mol Genet* 6:2247-55.
- Abdelhak S, Kalatzis V, Heilig R, Compain S, Samson D, Vincent C, Weil D, Cruaud C, Sahly I, Leibovici M, Bitner-Glindzicz M, Francis M, Lacombe D, Vigneron J, Charachon R, Boven K, Bedbeder P, Van Regemorter N, Weissenbach J, Petit C. 1997b. A human homologue of the *Drosophila* eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family. *Nat Genet* 15:157-64.
- Azuma N, Hirakiyama A, Inoue T, Asaka A, Yamada M. 2000. Mutations of a human homologue of the *Drosophila* eyes absent gene (*EYA1*) detected in patients with congenital cataracts and ocular anterior segment anomalies. *Hum Mol Genet* 9:363-6.
- Buller C, Xu X, Marquis V, Schwanke R, Xu PX. 2001. Molecular effects of *Eya1* domain mutations causing organ defects in BOR syndrome. *Hum Mol Genet* 10:2775-81.

Formatted: English (U.S.)

- 1
2 Chang EH, Menezes M, Meyer NC, Cucci RA, Vervoort VS, Schwartz CE, Smith RJ. 2004.
3 Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic
4 consequences. *Hum Mutat* 23:582-9.
5
6
7 Charbonnier F, Raux G, Wang Q, Drouot N, Cordier F, Limacher JM, Saurin JC, Puisieux A,
8 Olschwang S, Frebourg T. 2000. Detection of exon deletions and duplications of the
9 mismatch repair genes in hereditary nonpolyposis colorectal cancer families using
10 multiplex polymerase chain reaction of short fluorescent fragments. *Cancer Res* 60:2760-3.
11
12
13 Chen A, Francis M, Ni L, Cremers CW, Kimberling WJ, Sato Y, Phelps PD, Bellman SC,
14 Wagner MJ, Pembrey M et al. 1995. Phenotypic manifestations of branchio-oto-renal
15 syndrome. *Am J Med Genet* 58:365-70.
16
17
18 Epstein JA, Neel BG. 2003. Signal transduction: an eye on organ development. *Nature*
19 426:238-9.
20
21
22 Fraser FC, Ling D, Clogg D, Nogrady B. 1978. Genetic aspects of the BOR syndrome--
23 branchial fistulas, ear pits, hearing loss, and renal anomalies. *Am J Med Genet* 2:241-52.
24
25 Fraser FC, Sproule JR, Halal F. 1980. Frequency of the branchio-oto-renal (BOR) syndrome
26 in children with profound hearing loss. *Am J Med Genet* 7:341-9.
27
28
29 Hoskins BE, Cramer CH, Silvius D, Zou D, Raymond RM, Orten DJ, Kimberling WJ, Smith
30 RJ, Weil D, Petit C, Otto EA, Xu PX, Hildebrandt F. 2007. Transcription factor SIX5 is
31 mutated in patients with branchio-oto-renal syndrome. *Am J Hum Genet* 80:800-4.
32
33
34 Kochhar A, Orten DJ, Sorensen JL, Fischer SM, Cremers CW, Kimberling WJ, Smith RJ.
35 2008. SIX1 mutation screening in 247 branchio-oto-renal syndrome families: a recurrent
36 missense mutation associated with BOR. *Hum Mutat* 29:565.
37
38
39 Melnick M, Bixler D, Silk K, Yune H, Nance WE. 1975. Autosomal dominant
40 branchiootorenal dysplasia. *Birth Defects Orig Artic Ser* 11:121-8.
41
42
43 Melnick M, Hodes ME, Nance WE, Yune H, Sweeney A. 1978. Branchio-oto-renal dysplasia
44 and branchio-oto dysplasia: two distinct autosomal dominant disorders. *Clin Genet* 13:425-
45 42.
46
47
48 Mutsuddi M, Chaffee B, Cassidy J, Silver SJ, Tootle TL, Rebay I. 2005. Using *Drosophila* to
49 decipher how mutations associated with human branchio-oto-renal syndrome and optical
50 defects compromise the protein tyrosine phosphatase and transcriptional functions of eyes
51 absent. *Genetics* 170:687-95.
52
53
54
55
56
57
58
59
60

- 1
2 Ni L, Wagner MJ, Kimberling WJ, Pembrey ME, Grundfast KM, Kumar S, Daiger SP, Wells
3 DE, Johnson K, Smith RJ. 1994. Refined localization of the branchiootorenal syndrome
4 gene by linkage and haplotype analysis. *Am J Med Genet* 51:176-84.
5
6
7 Okada M, Fujimaru R, Morimoto N, Satomura K, Kaku Y, Tsuzuki K, Nozu K, Okuyama T,
8 Iijima K. 2006. EYA1 and SIX1 gene mutations in Japanese patients with branchio-oto-
9 renal (BOR) syndrome and related conditions. *Pediatr Nephrol*, 21:475-81.
10
11
12 Orten DJ, Fischer SM, Sorensen JL, Radhakrishna U, Cremers CW, Marres HA, Van Camp
13 G, Welch KO, Smith RJ, Kimberling WJ. 2008. Branchio-oto-renal syndrome (BOR):
14 novel mutations in the EYA1 gene, and a review of the mutational genetics of BOR. *Hum*
15 *Mutat* 29:537-44.
16
17
18 Ozaki H, Watanabe Y, Ikeda K, Kawakami K. 2002. Impaired interactions between mouse
19 Eyal harboring mutations found in patients with branchio-oto-renal syndrome and Six,
20 Dach, and G proteins. *J Hum Genet* 47:107-16.
21
22
23 Patrick AN, Schiemann BJ, Yang K, Zhao R, Ford HL. 2009. Biochemical and functional
24 characterization of six SIX1 Branchio-oto-renal syndrome mutations. *J Biol Chem*
25 284:20781-90.
26
27
28 Rayapureddi JP, Kattamuri C, Steinmetz BD, Frankfort BJ, Ostrin EJ, Mardon G, Hegde RS.
29 2003. Eyes absent represents a class of protein tyrosine phosphatases. *Nature* 426:295-8.
30
31
32 Rebay I, Silver SJ, Tootle TL. 2005. New vision from Eyes absent: transcription factors as
33 enzymes. *Trends Genet* 21:163-71.
34
35 Rickard S, Boxer M, Trompeter R, Bitner-Glindzicz M. 2000. Importance of clinical
36 evaluation and molecular testing in the branchio-oto-renal (BOR) syndrome and
37 overlapping phenotypes. *J Med Genet* 37:623-7.
38
39
40 Ruf RG, Berkman J, Wolf MT, Nurnberg P, Gattas M, Ruf EM, Hyland V, Kromberg J, Glass
41 I, Macmillan J, Otto E, Nurnberg G, Lucke B, Hennies HC, Hildebrandt F. 2003. A gene
42 locus for branchio-otic syndrome maps to chromosome 14q21.3-q24.3. *J Med Genet*
43 40:515-9.
44
45
46 Ruf RG, Xu PX, Silvius D, Otto EA, Beekmann F, Muerb UT, Kumar S, Neuhaus TJ,
47 Kemper MJ, Raymond RM Jr, Brophy PD, Berkman J, Gattas M, Hyland V, Ruf EM,
48 Schwartz C, Chang EH, Smith RJ, Stratakis CA, Weil D, Petit C, Hildebrandt F. 2004.
49
50
51
52
53
54
55
56
57
58
59
60

Formatted: German (Germany)

1
2 SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA
3 complexes. Proc Natl Acad Sci U S A 101:8090-5.
4

5 Sanggaard KM, Rendtorff ND, Kjaer KW, Eiberg H, Johnsen T, Gimsing S, Dyrmosse J,
6 Nielsen KO, Lage K, Tranebjaerg L. 2007. Branchio-oto-renal syndrome: detection of
7 EYA1 and SIX1 mutations in five out of six Danish families by combining linkage, MLPA
8 and sequencing analyses. Eur J Hum Genet 15:1121-31.
9

10 Shimasaki N, Watanabe K, Hara M, Kosaki K. 2004. EYA1 mutation in a newborn female
11 presenting with cardiofacial syndrome. Pediatr Cardiol 25:411-3.
12

13 Vincent C, Kalatzis V, Abdelhak S, Chaib H, Compain S, Helias J, Vaneecloo FM, Petit C.
14 1997. BOR and BO syndromes are allelic defects of EYA1. Eur J Hum Genet 5:242-6.
15

16 Xu PX, Adams J, Peters H, Brown MC, Heaney S, Maas R. 1999. Eya1-deficient mice lack
17 ears and kidneys and show abnormal apoptosis of organ primordia. Nat Genet 23:113-7.
18

19 Xu PX, Zheng W, Laclef C, Maire P, Maas RL, Peters H, Xu X. 2002. Eya1 is required for
20 the morphogenesis of mammalian thymus, parathyroid and thyroid. Development
21 129:3033-44.
22

23 Deleted: ¶
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legend

Figure 1 : Schematic representation of *EYA1* gene. Boxes represent *EYA1* exons. Mutations:

frameshift ◆, nonsense ●, missense ☆, splice site ✕, deletion

EyaHR: eyes absent homologous region.

Figure 2: Renal phenotypes in patients with an identified mutation.

Deleted: _____ ¶

Deleted: ¶
<sp>Figure 2 : Pedigree of patient 1064 and his twin sons (patients 1062 and 1063). . . <sp> . . . ¶
¶

Deleted: ¶

Formatted: Indent: Left: 0 pt, First line: 0 pt

Deleted: 3

Deleted: ~~~Section Break (Next Page)~

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient	Family history	Phenotype	Rare features	Gene	Exon or IVS	Nucleotide change	Protein change (conservation score**)	Polyphen	Mutation inheritance	Reference
346		T	b, f	<i>EYA1</i>	4	c.184C>T	p.Pro62Ser* (5)	Possibly damaging Score 1,851	I	this study
673		U	b, d (r : U)	<i>EYA1</i>	4	c.303C>A	p.Tyr101X	-	N	BTNRH, unpublished
383		T	b, p, r	<i>EYA1</i>	4	c.319G>A	p.Gly107Ser* (7)	Benign Score 0,456	N	this study
656		T	d, p, r, f	<i>EYA1</i>	5	c.430C>T	p.Gln144X	-	U	this study
1126	1126 patient's father	T	r, f, TOP	<i>EYA1</i>	7	c.586_596Dup (+)636_644delInsTG	p.Ser200IlefsX12	-	I	this study
1318		T	b, d, f						U	
1153		T	d, p, r, ie	<i>EYA1</i>	7	c.616dupT	p.Tyr206LeufsX50	-	U	this study
708		T	b, p, ee (d : U)	<i>EYA1</i>	7	c.670delC	p.Gln224SerfsX109	-	U	this study
311		T	d, p, ee, t	<i>EYA1</i>	7	c.722delC	p.Thr241LysfsX92	-	I	this study
523		T	d, p, ee, f (r : U)	<i>EYA1</i>	8	c.781C>T	p.Arg261X	-	U	Kumar et al, 1998
1215	BOR in her mother	T	b, r, ee, f						U	
326		T	b, p, f (d and r : U)	<i>EYA1</i>	8	c.783delA	p.Leu262CysfsX71	-	I	this study
327	326 patient's mother	T	b, d, f						U	
1291		A	b, p	<i>EYA1</i>	IVS8	c.867+5G>A	-	-	U	this study
1311		T	b, d, p, ee	<i>EYA1</i>	8	c.867_867+14del	p.Arg290GlufsX43	-	U	this study
314		T	b, d, p, ie, f	<i>EYA1</i>	IVS9	c.952-2A>G	-	-	I	Okada et al, 2006

Deleted: 199

Deleted: Arg

Deleted: 1

117		T	b, d, r							U	
332		A	r, ee (d : U)	Dysmorphic features, arched palate, unilateral ovarian agenesis	EYA1	10	c.982C>T	p.Arg328X	-	U	BTNRH, unpublished
347		T	b, p, r, ee							N	
512		T	b, d, p, r, ee, ie, f	Motor delay, cleft palate, lacrymal duct agenesis	EYA1	10	c.989A>T	p.Glu330Val* (9)	Probably damaging	I	this study
417	512 patient's mother	T	b, d, r, ee, ie, f						Score 2,568	U	
1056		T	b, p, ee, ie, t, f						-	I	
1057	1056 patient's father	T	d, p, ee, f	Facial asymetria	EYA1	10	c.1039G>T	p.Glu374X	-	U	this study
1282		T	b, d, p, r		EYA1	IVS 10	c.1042-1G>A	-	-	U	MORL
1288		T	b, d, p, r		EYA1	IVS 11	c.1100+1G>C	-	-	U	this study
693		T	b, d, r, ee, ie		EYA1	12	c.1216_1219dup	p.Arg407GlnsX13	-	U	this study
1194		T	b, p, r, ee, t	Crocodile tears syndrome	EYA1	12	c.1220G>A	p.Arg407Gln (5)	Possibly damaging	U	Kumar et al, 1997
1202	BOR in his father	T	b, d, f						Score 1.766	U	
1321		T	b, d, r, ee		EYA1	12	c.1231_1232dupAT	p.Tyr412SerfsX24	-	U	this study
780		T	b, p, f							I	
781		T	b, d, p, ee, f							I	
782	780 and 781 patients' mother	T	b, d, p		EYA1	12	c.1251delinsCC	p.Asn418GlnfsX10	-	L	Abdelhak et al, 1997
783	782 patient's grand-mother	T	d, f							U	
285		T	b, d, p, r, ee, ie, f							N	
286	285 patient's mother	T	b, d, p, r, f		EYA1	13	c.1372_1375dupTCCC	p.Arg459LeufsX41	-	U	this study
175		T	r, ee, f, (d : U), TOP	Fetal hypotrophia	EYA1	IVS13	c.1377-2A>G	-	-	I	BTNRH, unpublished
548	900 and 700 patients' father	T	b, d, p, f							U	
900		T	d, p, f		EYA1	14	c.1425delA	p.Leu476TrpfsX9	-	I	this study
700		T	r, f, TOP	Conotruncal cardiopathy						I	

Deleted: lle
 Deleted: 1
 Deleted: f
 Deleted: T>

Deleted: Ala
 Deleted: 5

710		T	b, p, r	Uvula agenesi	<i>EYA1</i>	14	c.1434dup	p.Val479SerfsX20	-	N	this study	Deleted: _1435 insA
497		A	p, d, ee	Crocodile tears syndrome	<i>EYA1</i>	14	c.1442T>C	p.Leu481Pro* (8)	Probably damaging Score 2,517	N	this study	
229		T	p, d, ie, f	Hypothyroidism	<i>EYA1</i>	14	c.1481A>G	p.Tyr494Cys (8)	Probably damaging Score 3,048	U	BTNRH, unpublished	
148		T	b, d, p, r, ie, t		<i>EYA1</i>	15	c.1542_1546delAAAAG	p.Arg514SerfsX83	-	U	this study	
953		T	b, d, r	Lacrymal duct stenosis	<i>EYA1</i>	15	c.1554T>G	p.Tyr518X	-	U	this study	
1014		A	d, t		<i>EYA1</i>	16	c.1607T>C	p.Met536Thr* (9)	Probably damaging Score 2,723	U	this study	
483		T	d, p, r, ee, ie		<i>EYA1</i>	16	c.1655dup	p.His552GlnfsX47	-	I	this study	
1265		T	d, p, r		<i>EYA1</i>	16	c.1678T>C	p.X560Gln*	-	U	this study	
1062		T	b, d, r, t, f							I		
1063	1062 patient's brother	T	d, r, f		<i>EYA1</i>	3, 4 and 5	c.104-?_461+?del	-	-	I	this study	
1064	1062 and 1063 patients' father	T	b, d, t, r, f							U		
1216		T	b, d, p (r : U)		<i>EYA1</i>	8-16	c.727-?_1680+?del	-	-	U	this study	
608		T	b, d, p, r, ee	Cutaneous mastocytosis, hypoplasia of the triangular muscle of the lip, hypermetropia	<i>EYA1</i>	-	Entire gene deletion	-	-	N		
821		T	b, d, r, ee, t, f	Micrognathia, feeding troubles, central and obstructive apnea						I		
798	821 patient's mother	T	b, d, ee, f							U		
991		T	b, d, p, r	Facial asymmetry						N		
714		U	b (d : U)		<i>SIX1</i>	1	c.386A>G	p.Tyr129Cys	Probably damaging Score 2,945	I	Ruf et al, 2004	
715	714 patient's father	U	b, ee (d : U)							U		

1226	A	b, p		<i>SIX1</i>	IVS 1 + 3	c.560+3A>T	-	-	U	this study
162	T	r, f	Lacrymal duct stenosis	<i>SIX1</i>	2	c.746C>T	p.Pro249Leu* (7)	Possibly damaging Score 1,806	U	this study

Table 1 : mutations and phenotypes in patients with BOR syndrome. : T : typical BOR, A : atypical BOR, b : branchial anomalies, d : deafness, p : pits, t : tags, ie : inner ear, me : middle ear, ee : extern ear anomalies, r : renal anomalies, f : familial, U : unknown, TOP : termination of pregnancy, I : inherited, N : de novo. BTNRH and MORL : Boys Town National Research Hospital and Molecular Otolaryngology Research Laboratory (UI, USA), see <http://www.healthcare.uiowa.edu/labs/pendredandbor/>. * : not found in 92 healthy individuals. ** : according to ConSurf (<http://consurftest.tau.ac.il/>). The reference sequences for numbering are NM_172060.2 for *EYA1*, NM_005982.3 for *SIX1* and NM_175875.4 for *SIX5*.

Formatted: French (France)

Formatted: Font: (Default) Arial, 8 pt, English (U.K.)

Formatted: Font: (Default) Arial, 8 pt

Formatted: Font: (Default) Arial, 8 pt, English (U.K.)

Formatted: Font: (Default) Arial, 8 pt, Not Bold, English (U.K.)

Formatted: Font: Not Bold

Formatted: Font: (Default) Arial, 8 pt, Not Bold, English (U.K.)

Formatted: Font: (Default) Arial, 8 pt, Not Bold, English (U.K.)

Formatted: Font: (Default) Arial, 8 pt, Not Bold, English (U.K.)

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For Peer Review

	Total		With a mutation		No mutation	
	n	%	n	%	n	%
Renal anomalies	89	65%	31	53%	58	72%
Deafness	88	64%	40	68%	48	59%
Pits	56	41%	33	56%	23	28%
Branchial defects	55	40%	37	63%	18	22%
Tags	31	23%	8	14%	23	28%

Table 2 : clinical features of the whole population (n=140). Columns with and without mutation represent the ratio of patients with each symptoms reported on the total number of patients with (n=59) or without (n= 81) mutation, respectively

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For Peer Review

	Deafness	No deafness	Total
Missense	8	2	10
Truncating	24	12	36
Deletion	8	1	9
	40	15	55

	Renal symptoms	No renal symptom	Total
Missense	5	5	10
Truncating	18	18	36
Deletion	7	2	9
	30	25	55

	Pits	No pit	Total
Missense	6	4	10
Truncating	22	14	36
Deletion	4	5	9
	32	23	55

	Branchial symptoms	No branchial symptom	Total
Missense	6	4	10
Truncating	22	14	36
Deletion	6	3	9
	34	11	55


Table 3: type of *EYA1* mutation according to the type of symptom.

Deleted: ¶

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47


For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Schematic representation of EYA1 gene. Boxes represent EYA1 exons. Mutations: frameshift □, nonsense □, missense ●, splice site ◇, deletion ◆. EyaHR: eyes absent homologous region.
169x94mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Renal phenotypes in patients with an identified mutation.
160x100mm (300 x 300 DPI)